SPARTANBURG COMMUNITY CLINICAL ONCOLOGY PROGRAM

斯帕坦堡社区临床肿瘤学计划

• 批准号: 3557530
• 负责人: James D Bearden
• 金额: $ 18.49万
• 依托单位: SPARTANBURG REGIONAL MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-09-01 至 1996-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3557530
• 关键词: 13 cis retinoate; Hodgkin's disease; acute leukemia; acute lymphocytic leukemia; adenocarcinoma; antineoplastics; behavioral medicine; biomarker; bladder neoplasm; bleomycin; breast neoplasms; cancer information system; cancer prevention; cancer registry /resource; cancer rehabilitation /care; cancer risk; cervix neoplasms; chemoprevention; cis platinum compound; clinical trials; colorectal neoplasms; combination chemotherapy; community health services; continuing education; cooperative study; cyclophosphamide; cystectomy; cytogenetics; cytosine arabinoside; dacarbazine; daunorubicin; doxorubicin; early diagnosis; etoposide; flow cytometry; fluorouracil; germ cell neoplasms; head /neck neoplasm; human subject; human therapy evaluation; hydroxyurea; ifosfamide; interferons; leucovorin; levamisole; lomustine; lung neoplasms; lymphoma; mammography; mechlorethamine; melanoma; methotrexate; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer education; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer nutrition therapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer therapy; nutrition related tag; oral leukoplakia; ovary neoplasms; paclitaxel; pancreas neoplasms; patient /disease registry; patient care management; peptide hormone analog; pharmacy administration; prednisone; primary care physician; procarbazine; prostate neoplasms; quality of life; regional medical planning; relaxation; small cell lung cancer; smoking cessation; tamoxifen; testis neoplasms; tocopherols; trimetrexate; vincristine

The Spartanburg Community Clinical Oncology Program (SCCOP) has been an enthusiastic participant in the CCOP program since its inception. Since 1983 SCCOP has accrued greater than 10% of all newly diagnosed cancer patients in our regional tumor registry to cancer treatment protocols with data of high quality and low cost per accrual in this rural CCOP. The average accrual per year of 102 compares favorably with the average yearly treatment accrual CCOP wide of 86 as stated in the RFA. The SCCOP accrued 100 subjects to cancer control protocols in FY-06, equivalent to the average accrual CCOP wide of 109.6 subjects per year as stated in the RFA. SCCOP believes that participation in NCI approved cancer treatment and cancer control protocol activities is an ideal way to bring state-of-the- art cancer treatment and cancer control research to members of our community and involve a wider segment of our community in such activities. This participation will transfer newly developed technology in cancer prevention, early detection, treatment, patient management, rehabilitation and continuing care to our community in an accelerated fashion and correspondingly reduce cancer incidence, morbidity and mortality. The goals of the SCCOP for this grant period are to maintain and expand our cancer treatment accruals and to develop a comprehensive cancer control trials program. This will be accomplished by enlisting a larger number of subspecialty investigators (ENT, urology, surgical oncology, gynecology) in cancer treatment and cancer control activities, and encompassing both the family practice residency program at Spartanburg Regional Medical Center and private practice primary care physicians in cancer control activities. The SCCOP will continue to affiliate with SWOG, CCWFU, NSABP, and MDACC as research bases. The grant will support three full-time equivalents for data management. The consortium hospitals, as a measure of their commitment to the CCOP program, are providing significant funding for one FTE (secretary/data manager) and additional funds for travel and cancer control data management activities. The SCCOP enthusiastically recompetes at this time for continued funding for an activity which has proven extremely rewarding for this community.

斯帕坦堡社区临床肿瘤学项目（SCCOP）一直是一个 自CCOP计划成立以来，我就一直热情参与该计划。 以来 1983年SCCOP占所有新诊断癌症的10%以上 我们区域肿瘤登记处的患者接受癌症治疗方案， 高质量的数据和低成本的每应计在这个农村CCOP。 的 平均每年应计102美元， RFA中所述的治疗累积CCOP范围为86。 SCCOP在2006财年为癌症控制方案招募了100名受试者， 相当于每年109.6例受试者的平均累积CCOP， 在RFA中表示。 SCCOP认为，参与NCI批准的癌症治疗， 癌症控制协议活动是一个理想的方式，使国家的- 艺术癌症治疗和癌症控制研究的成员，我们的 我们的社区和参与更广泛的社会阶层在这些活动。 此次参与将转让新开发的癌症技术 预防、早期发现、治疗、患者管理、康复 并以加速的方式继续关心我们的社区， 相应降低癌症发病率、发病率和死亡率。 SCCOP在此资助期内的目标是维持和扩大我们的 癌症治疗累积和发展一个全面的癌症控制 审判程序。 这将通过招募更多的 亚专业研究者（耳鼻喉科、泌尿外科、外科肿瘤学、妇科）， 癌症治疗和癌症控制活动，并包括 斯帕坦堡地区医疗中心的家庭实践住院医师计划 和私人执业初级保健医生在癌症控制活动。 SCCOP将继续与SWOG、CCWFU、NSABP和MDACC建立联系， 研究基地。 该补助金将支持三个全职等同于 数据管理功能 医院联盟，作为衡量他们 对CCOP计划的承诺，正在为一个 FTE（秘书/数据管理员）和用于差旅和癌症的额外资金 控制数据管理活动。 SCCOP在这个时候热情地重新竞争继续资助 这一活动对这个社区来说意义非凡